CTOs on the Move

B-One

www.b1.co

 
A few individuals with decades of experience in the U.S. orthopedic industry,came together in 2015 because they saw the need for a first-class company that was Agile,creative and innovative in a global market subject to advancing technologies and changing policies.They had seen the successes of the large companies, but they had witnessed compromises that had to be made.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.b1.co
  • 636 Shelby Street 4th Floor
    Bristol, TN USA 37620
  • Phone: N/A

Executives

Name Title Contact Details

Funding

B-One raised $14M on 03/03/2020

Similar Companies

Vision infonet

Vision infonet is a Naperville, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ProSomnus

ProSomnus is the first manufacturer of precision, mass-customized Precision Oral Appliance Therapy devices to treat OSA, which affects over 74 million Americans and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity and type 2 diabetes. ProSomnus`s patented devices are a more comfortable and less invasive alternative to Continuous Positive Airway Pressure (CPAP) therapy, and lead to more effective and patient-preferred outcomes. With more than 150,000 patients treated, ProSomnus`s devices are the most prescribed Precision Oral Appliance Therapy in the U.S.

Adagio Medical

Adagio Medical, Inc. is a privately held company located in Laguna Hills, California developing innovative cryoablation technologies that create continuous, linear, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter and ventricular tachycardia.

Tearlab

TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.

hppi

hppi is a Irving, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.